A challenge to the orthopaedic surgeon in the 21st century is the desire of the ageing patient to remain physically and mentally active and to continue to contribute to society. Younger patients are participating in more physically demanding sporting activities, resulting in injuries that require biological solutions which can allow them to continue to be active throughout their lifetime. Considerable benefits have resulted from the biomechanical solutions of the past 50 years, with better biomaterials and implants for joint replacements, more precise instrumentation and computer-aided navigation techniques. However, implants have a finite lifespan owing to loosening or other modes of failure and may require further surgery involving increased morbidity for the patient. The future lies in regenerative medicine, with the potential to grow new tissues and organs to replace damaged or diseased ones by utilising stem cells, which have the capacity to self-renew and differentiate into many different types of tissue. Although this area of research holds infinite promise, it is also influenced by scientific, ethical, moral and political controversies. This review aims to provide a better understanding of the issues concerning stem cell research, as well as the potential therapeutic use of these cells in orthopaedic surgery.
What are stem cells?
Stem cells must have a capacity for selfrenewal giving rise to more stem cells, and the ability to differentiate into tissues of various lineages under appropriate conditions. They may be pluripotent or multipotent, depending on type. Only the embryo is totipotent. Embryonic stem cells (ESCs) are pluripotent, as they are capable of differentiating into many tissue types, whereas differentiation of adult stem cells is generally restricted to the tissue in which they reside, as with hepatocytes in the liver, and haemopoietic stem cells in blood (Fig. 1) . 1 However, under appropriate conditions some can differentiate into multilineages, becoming multipotent. This is true of mesenchymal stem cells (MSCs), which are found in bone marrow, skin, adipose tissue, and many other tissues of mesenchymal origin. These cells are capable of differentiating into bone, cartilage, tendon, ligament, fat and other tissues of mesenchymal origin. 2 Recently, a more pluripotent stem cell, the multipotent adult progenitor cell (MAPC) 3 has been isolated from bone marrow.
There is also the phenomenon of transdifferentiation, in which cells from one lineage dedifferentiate, giving rise to an intermediate cell type, before redifferentiating into cells of another lineage. This can be seen in a number of tissues such as the heart, liver and brain and is not due to the fusion of different kinds of lineage progenitor cells which exist in the tissues. Badorff et al 4 cultured endothelial progenitor cells (EPCs) with cardiomyocytes in vitro and found a significant increase in length and size to form a cardiomyocyte-like morphology which expressed α -sarcomeric actinin. They decreased the formation of a gap at the junction between the EPCs and cardiomyocytes, and concluded that the EPCs had transdifferentiated into cardiomyocytes through the coculture. This phenomenon was not seen in EPCs which were cultured in a cardiomyocyteconditioned medium, indicating that cell-tocell contact rather than cell fusion had induced the transdifferentiation. Song and Tuan 5 demonstrated that transdifferentiation is achieved by the dedifferentiation and redifferentiation of lineage cells. In their experiment, human MSCs were first introduced into osteo-, chondro-and adipo-lineages. They were then cultured, grown, and induced to another lineage of cells. This experiment also demonstrated that the shift of lineage is not caused by cell fusion or heterogeneity.
Derivation of ESCs
In mammals, the fertilised oocyte, zygote and morula resulting from the cleavage of early embryos are examples of pluripotent cells.
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The main source of pluripotent ESCs is the inner cell mass (ICM) of the five to six-day-old human blastocyst. In embryogenesis, the ICM develops into two distinct cell layers, the epiblast and the hypoblast. The hypoblast forms the yolk sac, which eventually becomes redundant in humans. The epiblast differentiates into three layers, namely the ectoderm, mesoderm and endoderm. Under controlled laboratory conditions this ICM can be isolated and cultured with feeder cells to establish colonies of human embryonic stem cells (hESCs) (Fig. 2) . 7, 8 A successful test of the pluripotency of a stable hESC line is its ability to differentiate into ectoderm, mesoderm and endoderm when injected into animals. Controlled differentiation can be accomplished by treating hESCs biochemically with either specific agents such as growth factors to generate a specific cell type, or through direct contact with companion cells in a co-culture. For example, cardiomyocytes have been produced in vitro in a co-culture environment with hESCs. Alternatively, a specific gene construct can be transfected into ESCs and the gene then switched on so as to direct the hESC to differentiate along the desired pathway. However, the therapeutic application of ESCs may still be a long way off. There are many ethical, scientific and political challenges to overcome in the research into ESCs.
Ethical issues
There is universal agreement that reproductive cloning, i.e. making a whole human being, is prohibited. However, there are different views concerning therapeutic cloning and research on ESCs. Many countries allow the use of ESCs derived from discarded or excess embryos from in vitro fertilisation (IVF). 9 However, there are differences of opinion regarding the derivation of new stem cell lines from embryos created specifically for research purposes. The United States does not allow the use of federal funds for research to create new ESC lines, but allows work on the ESC lines currently stored in the National Institute of Health (NIH). However, there is no regulation of research on ESCs carried out with private funding, resulting in the establishment of privately funded research centres.
Despite the discrepancy between the approaches of different governments, scientists from various countries have come together to form the International Stem Cell Forum (ISCF 
Overcoming problems with ESCs
There are significant hurdles to overcome in the development of cell-based therapy from hESCs. They need to be coaxed into forming a more stable progenitor stage before being administered to humans to avoid the formation of 10 MSCs can also be derived from periosteum, fat and skin. They are multipotent cells capable of differentiating into cartilage, bone, muscle, tendon, ligament and fat. 11 The ability of MSCs to differentiate into many types of musculoskeletal tissue has great potential in the repair and regeneration of bone and cartilage. This has prompted scientists to study the biology of these cells so that they can be appropriately converted to the desired tissues with the proper biological and mechanical properties. In our institution we are studying the biology of stem cells with respect to characterisation, differentiation, and expansion of MSCs. With appropriate growth factors and scaffold technology, it is envisaged that in the near future it will be possible to repair large defects in bone and cartilage biologically.
Mesenchymal stem cells
MSCs are multipotent progenitor cells which are capable of differentiating into several connective tissue cell types, including osteocytes, chondrocytes, adipocytes, tenocytes and myocytes. 11 They are characterised by cell surface markers and, under appropriate conditions, can be induced to differentiate into bone, cartilage, muscle and fat. MSCs from bone marrow share the following features.
1. No expression of HSC markers, such as CD34 and CD14.
2. Expression of matrix receptors such as CD44, CD29 and CD71.
3. Expression of MSC markers, SH2 (CD105) and SH3 (CD71). 12 4. Extracellular matrix components: collagen, proteoglycans and fibronectin.
Growth factors and cytokine receptors for TGF-
The profiling of gene expression between human bone marrow stromal cells (BMSCs) and adipose-derived stromal cells (ADSCs) has been compared in our institution. The bone marrow of five human donors and adipose tissue from another five were run through an F8 matrix human genome U133A gene chip, each of which represents 33 000 human genes. The human universal reference RNA, which is commercially available, was used as a comparison background. We found that BMSCs and ADSCs shared certain common genes which were up-regulated and downregulated as BMSCs and ADSCs underwent chondrogenic or osteogenic differentiation. 13, 14 Current research is aimed at further understanding the role of these genes.
Using appropriate induction solutions, MSCs have been shown to be capable of differentiating into bone, cartilage, muscle and adipose tissue. Chondrogenic differentiation with genetic modulation has been attempted by transfecting stem cells with recombinant DNA constructs and coding for the expression of certain growth factors or proteins that promote chondrogenesis, such as SRY-box containing genes (SOX) 5-9, insulin-like growth factor (IGF)-1 and transforming growth factor (TGF)-β .
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Adult stem cells in orthopaedic research
Research on the therapeutic application of MSCs can be carried out by using MSCs as progenitor cells, injected directly into tissues to enhance the process of repair, or by using them as a vehicle for gene delivery.
Articular cartilage
Articular cartilage is vulnerable to injury and has poor potential for repair. Damage can lead to arthritic changes many years after injury. 16 Procedures directed at the recruitment of stem cells from the marrow by penetration of the subchondral bone have been widely used to treat localised cartilage defects. The 'microfracture' technique is often used, but the fibrocartilage which results from these techniques has poor mechanical properties compared with normal cartilage. 17 Nevertheless, good short-to intermediate-term results from treating the lesions of osteochondritis dissecans or traumatic osteochondritis with these techniques have been described. 18, 19 More recently, attempts to 'regenerate' normal articular cartilage have been introduced in clinical practice with autologous chondrocyte implantation (ACI). Bentley and Greer 20 were among the first to show that chondrocytes could be transplanted into articular cartilage defects, which improved healing compared with that in controls. Chondrocytes, 21 stem cells, 22, 23 periosteum containing stem cells, chondrocyte precursors or any combinaton of these can be used. 24 Recently Hui et al 25 investigated the efficacy of periosteal graft, osteochondral autograft (mosaicplasty), autologous chondrocytes and MSC transplants in the treatment of chondral lesions in animal models. Gross histological and biomechanical examination after 36 weeks showed that the cultured chondrocytes and MSCs had comparable enhancing effects on the repair of chondral defects in advanced osteochondritis dissecans. Mosaicplasty seemed to do well initially, but deteriorated over time. Periosteal grafts were also shown to do less well. 25 
Bone
Trauma and some pathological conditions may lead to extensive loss of bone which requires transplantation of bone tissue or bone substitutes to restore structural integrity. The use of autologous and allogenic bone grafts is associated with donor site morbidity and the possible transmission of infection. Several researchers have described the purification and expansion of bone marrow cells from mice, rats, rabbits, dogs and humans, and the ability of these cell populations to form bone when implanted ectopically with hydroxyapatite or an appropriate carrier. [26] [27] [28] Methods have also been developed for the expansion of bone marrow osteoprogenitors, which indicates the possibility of using autologous human stromal progenitors in the regeneration of large bone defects. 29 Successful tissue engineering of bone requires osteoproduction, osteoinduction, osteoconduction and mechanical stimulation. Osteoproduction is the ability of the cell to secrete bone material. Bruder et al 28 and Bruder, Fink and Caplan 30 obtained healing of critically sized bone defects with purified MSCs derived from bone marrow. Quarto et al, 31 used autologous MSCs to treat segmental bone defects in a limited group of patients for whom a traditional therapeutic alternative was very difficult or had already failed. Recently, muscle-derived stem cells have received much attention as a source of osteoproductive cells. 32 Osteoinduction refers to the growth factors that attract osteogenic cells to the site of the defect. In recent years the isolation of factors such as TGF-β 3 and its analogues, bone morphogenetic proteins (BMPs), BMP-2 and BMP-7, has led to their use clinically to enhance and accelerate the repair of bone, and also to replace it. Osteoconduction relies on the incorporation of a structure bearing bone cells into a recipient site. The graft serves as a scaffold which is eventually replaced and remodelled. Yoshikawa and Myoui 33 have described the successful use of osteoconduction in bone tissue engineering. Mechanical stimulation may also help. Wiesmann, Joos and Meyer 34 found that mechanical stimulation and other biophysical stimuli appear to be critical factors for the proliferation and differentiation of bone cells and for the formation of both bone mineral and structure.
Bone induction to assist and enhance bone deposition and repair was introduced by Urist in 1965 35 and led to the isolation of the BMPs, which could stimulate osteogenic precursor MSCs to form bone. A number of studies have shown the potential for BMP-2, BMP-3 and BMP-4 in the healing of fractures and segmental bone defects, and in the fixation of prosthetic implants. 36 , 37 Lieberman et al 38 used
rat bone marrow-derived cells transduced with BMP-2 to heal critically-sized femoral defects and observed more robust formation of bone than in the control group. BMP regulates chemotaxis, mitosis and differentiation, and is fundamental in initiating fracture repair. 39 Other growth factors, such as TGF-β and IGF may stimulate fracture repair and minimise the rate of nonunion. 32 In order for BMP to induce bone formation effectively, its dose must be of sufficient concentration for a sustained period. However, these proteins have short biological half-lives and must be maintained at therapeutic concentrations at the fracture site to be effective. Gene therapy has been used to deliver therapeutic doses of protein for sustained periods. 40 Developments in gene therapy may allow the gene encoding for a given growth factor to be isolated and transferred to a recipient cell using viral or non-viral vectors. One potential advantage of the ex vivo gene delivery approach is that the genetically modified cells both secrete the BMP protein and respond to it, thereby potentially magnifying the clinial response. 41 Direct injection of adenoviral vectors carrying the BMP-2 gene has also shown promising results in a rabbit model of nonunion of bone. 42 Muscle tissue has received much attention for its potential as a gene delivery vehicle. Young et al 32 reported the successful use of musclederived stem cells as a vehicle capable of producing sufficient levels of osteoinductive proteins, such as BMP-2, after transduction with viral vectors. Muscle-derived cells, coupled with ex vivo gene therapy, can heal critically sized bony defects. 32 Shen et al 43 demonstrated that systemically injected IGF-1 transduced MSCs are able to return to and repopulate the bone marrow. More importantly, these cells localise preferentially to a fracture site and accelerate healing. 43 As yet, there have been no clinical trials of gene therapy for tissue repair.
Tendons and ligaments
Injuries to tendons and ligaments heal by forming inferiorquality tissue. Autografts, allografts and resorbable biomaterials have been used to repair defects in tendons and ligaments. [44] [45] [46] [47] The problems associated with biological grafts include donor site morbidity, scarcity, and tissue rejection.
A number of studies on the use of MSCs to improve the repair of tendon defects have been carried out in animals. Young et al 48 showed that when MSCs were seeded on a defect of 1 cm in the tendo Achillis of a rabbit, the repair had a significantly larger cross-sectional area and the collagen fibres appeared better aligned than those in matched controls. In another study, MSCs seeded with collagen composites were implanted into full-thickness central defects created in the patellar tendons of the animals providing the cells. 49 The healing of these autologous defects was compared with the natural repair of identical lesions on the contralateral side. The repairs containing the MSCcollagen composites showed significantly higher maximum stresses and moduli at 12 and 26 weeks than those which healed naturally, although greater concentrations of MSCs produced no additional significant histological or biomechanical improvement. 49 However, in these studies, as collagen gel could not be used alone as a control it would not contract without cells. Ouyang et al 50 used knitted polylactide-coglycolide (PLGA) as a scaffold loaded with MSCs in the repair and regeneration of the tendo Achillis of rabbits. Their results suggest that this construct has the potential to regenerate and repair such defects and to restore structure and function effectively. 50 One of the keys to success in surgical reconstruction of the anterior cruciate ligament (ACL) is the healing of the tendon graft to the bone. The normal anatomy of the insertion site of the ACL is fibrocartilaginous and consists of four distinct zones: ligament substance, unmineralised fibrocartilage, mineralised fibrocartilage and bone. 51 Conventional free tendon transfers are unable to restore this complex anatomy within the first six months. 52 A number of studies have been performed on the use of growth factors and biomaterials to improve tendon-to-bone healing. Rodeo et al 53 showed that BMP-2 can augment tendon healing in a bone tunnel. Hattersley et al 54 demonstrated in a rat model that tendons treated with BMP-12 form a fibrocartilaginous insertion after four weeks. Recently, Lim et al 55 studied the role of MSCs at the tendon-bone junction during reconstruction of the ACL in the rabbit. They showed that applying MSCs to tendon grafts at the tendonbone junction results in a zone of fibrocartilage at the junction which more closely resembled that of the normal ACL. These enhanced grafts have improved biomechanical properties compared with controls, and have exhibited a rapid and significant increase in load to failure and stiffness in the first eight weeks after reconstruction of the ACL. 55 
Meniscus
Tears in the avascular inner third of the meniscus have limited or no potential for repair as the reparative process cannot occur without the presence of bleeding. The standard biological healing process produces limited results. Meniscectomy has been shown to have a strong association with the subsequent development of osteoarthritis. 56, 57 Recently, cell-based therapy for meniscal injuries has been attempted. It has been demonstrated that isolated chondrocytes seeded on to meniscal matrices 58 were able to bond separate pieces together. Histological and biomechanical analyses showed that the strength of the adhesion increased over time by the formation of a newly synthesised cartilaginous matrix. Dutton et al 59 assessed the capability of autologous seeded BMSCs to repair an avascular meniscal lesion in the pig. They showed that a meniscal lesion involving the inner, avascular, one-third of the meniscus benefitted from the bonding capabilities of the transplant (Fig. 3) . These results represent a promising beginning for the potential of cellbased therapy to repair a tear in the avascular inner third of the meniscus rather than proceeding to surgical resection.
Spine
The intervertebral disc. Degeneration of the intervertebral disc is a leading cause of back pain and morbidity. Most patients are treated conservatively, with improvement in approximately 90%. After failure of conservative management the surgical options for discogenic back pain are limited and usually invasive. Most commonly, fusion with or without discectomy is performed, although more recently disc replacement has received some attention, and clinical trials have been reported to be fairly successful in the short term. 60 However, each of these therapeutic approaches aims to relieve the symptoms of disc degeneration, as opposed to treating its underlying cause. Cell-based tissue engineering offers considerable promise for a more biological alternative by transplantation to the intervertebral disc of mature autologous disc cells, chondrocytes or stem cells. Cell transplantation can potentially increase proteoglycan production, induce disc regeneration or slow the process of degeneration. In animal models, transplantation of autologous disc cells and chondrocytes derived from costal cartilage has been demonstrated to be feasible and may slow disc degeneration. 61 Recently, Crevensten et al 62 explored the use of MSCs for intervertebral disc regeneration. They used an in vivo model to investigate the feasibility of exogenous cell delivery, retention and survival in the pressurised disc space. MSCs were injected into the coccygeal discs of rats using 15% hyaluronan gel as a carrier. At seven and 14 days after injection, stem cells were still present within the disc but their numbers were significantly reduced. By 28 days a return to the initial number of injected cells was observed, and their viability was 100%. A trend towards increased disc height compared with the blank gel suggests an increase in matrix synthesis. The results indicate that MSCs can maintain viability and proliferate within the intervertebral disc of the rat. Although growth factors such as TGF-β 1 appear to have promising therapeutic properties, there is currently no practical method for the sustained delivery of exogenous growth factors to the disc for the management of disc degeneration. The introduction of appropriate genes into disc cells by gene transduction using adenoviral vectors or 'gene-gun' delivery systems holds some promise, but manufactured gene transfer is very expensive. Spinal fusion. The use of autologous bone is still considered to be the best method of obtaining a spinal fusion. Nevertheless, the rate of nonunion ranges from 5% to 35%. 63 Alternatives to this method have been investigated over many years. [64] [65] [66] It has been shown that BMPs with adequate carriers may achieve a similar, or even a higher rate of fusion than posterolateral fusion using autogenous bone graft. However, the use of BMPs is costly and there are possible adverse effects of these growth factors. 65 Recently a novel approach to create a hybrid graft by combining cultured MSCs with a ceramic scaffold has been tested. Cui et al 67 have described a similar study in which an osteoprogenitor cell line (D1-BAG) was cloned from mouse bone marrow cells and transplanted on a Matrigel carrier into the paraspinal bed in Nude rats, achieving successful fusion. Cinotti et al 68 found that cultured MSCs loaded into porous ceramic achieved a significantly higher rate of solid fusion than with porous ceramic alone, with a trend towards a higher rate of fusion than with autologous bone. Other studies using ectopic and orthotopic implantation sites showed successful bone formation with an autologous bone marrow-derived osteoprecursor cell population.
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Spinal cord. Stem cell therapy is thought to have considerable therapeutic potential for spinal cord injuries because of the ability of pluripotential cells to differentiate into neural tissue. However, repair of the spinal cord is very complex. It includes restoring or enhancing local spinal reflex arcs and reconnecting regenerating axons from above. Gliosis may block the outgrowth of axons. 70 Recently, evidence of axonal regeneration and functional recovery has been found in animal models of spinal cord injury. Akiyama et al 71 have demonstrated that MSCs isolated in culture from the mononuclear layer of bone marrow can remyelinate demyelinated spinal cord axons after direct injection into the lesion. Stem cells alone may not be enough to improve function in a damaged spinal cord.
Future strategies for repair of the human spinal cord will have to be multifaceted, with enhancement of axonal growth and reconnection, replacement of cellular elements, and the reversal of demyelination all being necessary steps for success. The connective tissue matrix, the degree of glial scarring and the central myelin inhibitory factors, elimination of which is required for axon outgrowth, are all important. The balance of these factors may be as important as the stem cells, and very difficult to optimise. 72 Rosenfeld and Gillett 72 have recently discussed the problems associated with the use of stem cells in this context and cautioned against premature application. They warned against extrapolating the results of animal experiments directly to humans, as there may be a risk of further morbidity and even tumour growth. Recent press reports from Korea and THE JOURNAL OF BONE AND JOINT SURGERY China on the successful use of stem cells in humans with spinal cord injury have been received with some scepticism. Further understanding of the mechanisms, and finding optimal targets for spinal cord regeneration, are necessary to obtain successful treatment for these patients.
Paediatric orthopaedics
Physis. Injuries to the physis often result in the formation of bony bridges between the epiphysis and the metaphysis. Of these injuries, 25% to 35% result in some shortening or angular deformity. 73 In older children correction can be obtained by stapling, epiphysiodesis or osteotomy, but treatment is more challenging in younger patients. Varying degrees of success have been achieved with excision of the bony bridge and the insertion of fat, 74 polymeric silicone 75 or muscle 76 as an interpositional material. 77 These inert fillers do not promote growth in the physis but serve only to prevent bony bridges from re-forming. 77 More recently, cultured chondrocytes have been transferred into physeal defects for the correction of established growth arrest in animal models. 78, 79 Tobita et al 80 found that transplantation of autologous chondrocytes cultured in atelocollagen gel reduced the angular deformity and length discrepancy of the leg with the injured physis to a greater degree than transplantation of fat in the rabbit.
Recently, attention has turned to the use of MSCs from bone marrow to repair physeal defects. These cells are particularly useful because of the ease of harvesting and their potential to differentiate into various types of cell, depending on the local environment. Chen et al 81 found that implantation of MSCs into growth-plate defects resulted in a significant reduction in growth arrest in the rabbit tibia. Ahn et al 82 evaluated the capacity of cultured MSCs to repair physeal defects. They embedded the cells in 10% gelatin in Gelfoam with TGF-β 3 and transferred them into growth-plate defects in the rabbit. They found markedly reduced angular deformity after partial physeal defects, and hypothesised that these donor MSCs differentiated into chondrocytes as well as the host bone marrow cells from the metaphyseal subchondral region, thereby generating the repair of the physis. 82 However, further studies need to be conducted to determine the size of the contribution by MSCs over host bone marrow to chondrogenesis in the physis. Muscular dystrophy. Muscular dystrophy is a term describing a heterogeneous group of neuromuscular disorders that produce progressive muscle weakness, muscle wasting, and, in the most severe cases, such as in Duchenne muscular dystrophy (DMD), paralysis and death. The current management of DMD involves pharmacological suppression of the inflammatory and immune responses, with only modest and temporary beneficial effects. Future approaches depend on cell and gene therapy and will require different strategies. The efficiency of cell transplantation might be improved through the use of stem cells. Wakitani et al 83 found that under certain conditions, in vitro bone marrow differentiates into contractile myotubes. An encouraging and pioneering experiment in mouse models of DMD demonstrated that myoblasts could be transplanted into dystrophic muscle and repaired a small proportion of damaged myofibres. Gussoni et al 84 showed that in immunodeficient mice a marrow-derived cell can migrate into areas of induced muscle degeneration, undergo myogenic differentiation and participate in the regeneration of the damaged fibres. Clinical application requires an abundant source of autologous stem cells, which could be corrected genetically by inserting a functional, appropriately regulated copy of a missing gene (for example dystrophin) and then transplanted in sufficient numbers by an appropriate delivery route. The delivery of dystrophin by in vivo gene transfer using viral vectors has been carried out, but the level restored has been quite low. The study showed that bone marrow-or muscle-derived stem cells appear to provide a means for systemic, rather than local, repair of muscle, as a consequence of the delivery of the cells throughout the vascular system. It is possible that in future the procedures for stem cell transplantation could be optimised to provide levels of engraftment of muscle that would be useful clinically. 85 Osteogenesis imperfecta. Osteogenesis imperfecta (OI) is a genetic disorder caused by defects in type I collagen. Ideally, the treatment of OI should be directed toward enhancing bone strength by improving the structural integrity of collagen. Pre-clinical studies have demonstrated that whole bone marrow contains cells that can engraft and become competent osteoblasts after transplantation. 86 Moreover, because collagen is a secreted product, even a low level of osteoblast engraftment might be beneficial to patients with OI. 87 Pereira et al 87 infused BMSCs from a normal mouse into irradiated transgenic recipient mice with an OI phenotype. Several months after transplantation the recipient mice demonstrated the presence of donor-derived MSCs in various organs, including bone, cartilage, lung and spleen. MSCs which homed to the bones differentiated into osteocytes and produced normal levels of collagen type I, with partial restoration of the osteogenesis imperfecta phenotype. 87 Similar results have been obtained after allogenic bone marrow transplantation in patients with OI. About 2% of the osteoblasts were of donor origin, suggesting that donor-derived MSC precursors in the marrow were capable of homing to the bone marrow and of differentiation into osteoblasts, or that residual osteoblasts in the bone marrow graft were able to establish in the bone marrow. 88 Potentially, genetic engineering of the individual's own bone marrow with ex vivo genetic modification, followed by transplantation back into the individual, might increase the amount of normal collagen while eliminating the need for a donor and for immunosuppression. MSCs transferred in a bone marrow graft may play a potential role in the correction of OI. However, controlled studies are required to further substantiate this effect.
Juvenile rheumatoid arthritis. Recent advances in stem cell technology and supportive therapy have reduced the morbidity and mortality of autologous stem cell transplantation (ASCT). This form of treatment has now been considered for 'autoimmune disorders', including a variety of rheumatological diseases. 89, 90 Anecdotal reports suggest that high-dose therapy supported by autologous stem cell transplantation may induce a good response in such disease. 91 Euler et al 92 have described several patients in whom autoimmune disease relapsed after autologous unmanipulated stem cell transplantation.
There has been a significant improvement in the management of rheumatic disease in children over the last decade. However, in many children treatment remains inadequate owing to poor disease control, drug toxicity, or a combination of the two. Recently, attempts at autologous stem cell transplantation have been made. 93 This technique involves first harvesting the patient's own HSCs, followed by aggressive treatment with irradiation and/or high-dose chemotherapy to destroy the cells that are responsible for the inflammatory disease. The patient's stem cells are then subjected to cycles of T-cell depletion before being infused back into the patient. The T cells are removed because of their potential to reintroduce the autoreactive state. Immune ablation followed by reconstitution of autologous haemopoiesis might allow 'resetting' of the immune system through the induction of peripheral tolerance. 93 Theoretically, it would be ideal to replace the immune system with allogenic stem cell transplantation. However, comparative studies have shown a higher morbidity and mortality associated with this procedure. Wulffraat, Sanders and Kuis 94 used ASCT to treat severe forms of juvenile chronic arthritis in four children. All showed a marked decrease in joint swelling, pain and morning stiffness without the use of antiinflammatory drugs for between six and 18 months, and the laboratory tests were returned to near normal values within six weeks. 94 At present, the use of ASCT for the treatment of human autoimmune disorders, including various rheumatic diseases, is in its infancy. Further clinical trials are necessary to develop this approach in patients with aggressive diseases for whom conventional treatment has failed. MSCs exhibit cell fusion properties as described by Goncalves et al. 95 Stem cell therapy holds great promise for the repair and regeneration of musculoskeletal tissues. In order to realise the full therapeutic potential of stem cells, a number of challenges need to be overcome. One of the most important prerequisites is to be able to generate adequate numbers of the correct phenotypes of cells under animal-free culture. This will require expertise in characterisation, differentiation and expansion of these cells. The regenerated tissue has to have the appropriate three-dimensional structure, with the production of extracellular matrix, and be structurally and biomechanically compliant with the demands of native tissue. Bioengineers will play an important role in this endeavour. Ultimately the tissue must be fully integrated and immunologically compatible, with the host tissue. Here the input from developmental biologists, molecular biologists and immunologists will be crucial. It is important to continue research to understand the basic biology of stem cells and their potential for clinical and therapeutic applications.
